REDWOOD CITY, Calif., Aug. 26, 2014 /PRNewswire/ -- Guardant Health, a healthcare company focused on the development and commercialization of oncology diagnostic products, has been recognized today by the World Economic Forum as a 2015 Technology Pioneer. As an innovator in non-invasive, tumor profiling, Guardant Health is one of 24 companies across a wide variety of industries and regions to receive this prestigious accolade.
Guardant360®, Guardant Health's first commercially available product, is a first-in-kind blood test that comprehensively sequences a patient's cancer in real-time to aid oncologists in making more informed, personalized treatment decisions without the cost, time, and risk of a traditional tissue biopsy. Guardant360 is built on Digital SequencingTM technology, a proprietary method of capturing and genomically profiling trace fragments of tumor DNA that are shed into the blood stream ("cell-free DNA"), while also providing sequencing information at the single-molecule level. A patient's cancer genomics continues to evolve and change over time due to treatment pressure, which can cause therapy failure. For the first time, oncologists now have a way to easily track tumor changes with a simple blood test.
In just two years, Guardant Health has taken a promising idea through clinical validation and to commercial launch. Since launch, Guardant360 has demonstrated strong clinical utility as 75% of the genomic alterations identified in the patient specimens are actionable.
"We are honored to be recognized by the World Economic Forum and humbled to be among the esteemed past and present award winners," said Helmy Eltoukhy, Ph.D., Co-founder and Chief Executive Officer of Guardant Health. "Our mission remains the same: to turn cancer into a manageable disease. We st
|SOURCE Guardant Health|
Copyright©2014 PR Newswire.
All rights reserved